Arbutus Biopharma Corp: Form 10-K for the period ended Dec 31, 2017
Filed with the SEC on Mar 16, 2018 and accepted by EDGAR at Mar 16, 2018, 08:44 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2017-10-01 to 2017-12-31 | $2.5m | us-gaap:Revenues |
| Revenue | 12 months2017-01-01 to 2017-12-31 | $10.7m | us-gaap:Revenues |
| Research and development | 12 months2017-01-01 to 2017-12-31 | $62.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-10-01 to 2017-12-31 | −$60.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2017-01-01 to 2017-12-31 | −$110.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2017-01-01 to 2017-12-31 | $261.0k | us-gaap:InterestExpense |
| Income tax | 12 months2017-01-01 to 2017-12-31 | −$24.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-10-01 to 2017-12-31 | −$36.8m | us-gaap:NetIncomeLoss |
| Net income | 12 months2017-01-01 to 2017-12-31 | −$84.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-10-01 to 2017-12-31 | −$0.67 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | −$1.56 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2017-01-01 to 2017-12-31 | −$1.56 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2017-01-01 to 2017-12-31 | 54,723,272 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | −$48.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | $7.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-12-31 | $54.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-12-31 | $129.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $237.2m | us-gaap:Assets |
| Current liabilities | At period end2017-12-31 | $14.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-12-31 | $54.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-12-31 | $182.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-18-003276. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.